Dexibuprofen: Pharmacology, therapeutic uses and safety

Inflammopharmacology

Volumn 11, Issue 4-6, 2003, Pages 371-383

  Kaehler, S T ^a   Phleps, W ^a   Hesse, E ^a  

^a Gebro Pharma GmbH   (Austria)

Author keywords

Dexibuprofen; Dose ratio; Pharmacology; Rac ibuprofen; Safety; Therapeutic uses

Indexed keywords

CELECOXIB; DEXIBUPROFEN; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANOREXIA; CLINICAL TRIAL; CONFERENCE PAPER; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEARTBURN; HUMAN; NAUSEA; PAIN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SIDE EFFECT; VISCERAL PAIN;

EID: 0842284227     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1163/156856003322699555     Document Type: Conference Paper

References (17)

1. Dionne, R. A. and McCullagh, L. (1998). Enhanced analgesia and supression of plasma β-endorphin by the S(+)-isomer of ibupropfen, Clin. Pharmacol. Ther. 63, 694-701.
2. Evans, A. M. (1992). Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steriodal anti-inflammatory drugs, Eur. J. Clin. Pharmacol. 42, 237-256.
3. Evans, A. M. (1996). Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S(+)-ibuprofen, J. Clin. Pharmacol. 36, S7-S15.
4. Hawel, R., Klein, G., Singer, F., et al. (2003). Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip, Int. J. Clin. Pharmacol. Ther. 41, 153-164.
5. Jamali, F. and Kunz-Dober, C. M. (1999). Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery, Br. J. Clin. Pharmacol. 47, 391-396.
6. Janjikhel, R. K. and Bricker, J. D. (1999). Stereoselective disposition of sustained release microphers of ibuprofen enantiomers in rats: II. Acute gastrointestinal toxicity, Drug Deliv. 6, 163-170.
7. Klein, G., Neff, H., Kullich, W., et al. (1992). S(+) versus racemic ibuprofen, Lancet 339, 681.
8. Langman, M. J. S., Weil, J. and Wainright, P. (1994). Risks of bleeding peptic ulcer associated with individual non-steriodal anti-inflammatory drugs, Lancet 343, 1075-1078.
9. Leising, G., Resel, R., Stelzer, F., et al. (1996). Physical aspects of dexibuprofen and racemic ibuprofen, J. Clin. Pharmacol. 36, 3S-6S.
10. Morihara, T., Chu, T., Ubeda, O., et al. (2002). Selective inhibition of Aβ42 production by NSAID R-enantiomers, J. Neurochem. 83, 1009-1012.
11. Rainsford, K. D. (Ed.) (1999). Pharmacology and toxicology of ibuprofen, in: Ibuprofen, a critical bibliographic review, pp. 145-275, Taylor & Francis, London.
12. Rudy, A. C., Bradley, J. D., Ryan, S. I., et al. (1992). Variability in the disposition of ibuprofen enantiomers in osteoarthritis patients, Ther. Drug Monitoring 14, 464-470.
13. Singer, F., Mayrhofer, F., Klein, G., et al. (2000). Evaluation of the efficacy and dose-response relationship of dexibuprofen (S(+)-ibuprofen) in patients with osteoarthritis of the hip and comparison with racemic ibuprofen using the WOMAC osteoarthritis index. Int. J. Clin. Pharmacol. Ther. 38, 15-24.
14. Tseng, C.-C. and Wolfe, M. M. (2000). Nonsteriodal anti-inflammatory drugs, Adv. Gastroenterol. 84, 1329-1344.
15. Vanderhoek, J. Y. and Bailey, M. J. (1984). Activation of a 15-lipoxygenase/leukotriene pathway in human polymorphonuclear leucocytes by the anti-inflammatory agent ibuprofen, J. Biol. Chem. 259, 6752-6756.
16. Vanderhoek, J. Y., Ekborg, S. L. and Bailey, M. J. (1984). Effects of cell growth, differentiation, and transformation: clinical involvement of leucotrienes, J. Allergy Clin. Immunol. 74, 412-416.
17. Villanueva, M., Heckenberger, H., Palmer, S. M., et al. (1993). Equipment inhibition by R-(-)-, S-(+)- and racemic ibuprofen of human polymorphonuclear cell function in vitro, Br. J. Clin. Pharmacol. 35, 235-242.